Update on rufinamide in childhood epilepsy

@inproceedings{Coppola2011UpdateOR,
  title={Update on rufinamide in childhood epilepsy},
  author={Giangennaro Coppola},
  booktitle={Neuropsychiatric disease and treatment},
  year={2011}
}
Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007. In January 2009, rufinamide was approved by the United States Food and Drug Administration for treatment of LGS in children 4 years of… CONTINUE READING
1 Extracted Citations
43 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…